Please Scroll Down to See Forums Below
Nolvadex Will Not Get Rid Of Gyno
- Thread starter el cubano
- Start date
And he breaks out the medical study results
winstrol69
New member
BITCH SLAPPED!
nandi12 said:
Actually, I'm not trying to slam you, but that is a bullshit study. Where did you get it from? Either way, notice the recurrence thus meaning that it did NOT get rid of the gyno . It also doesn't state if the gyno came about naturally or not. 3cm is big, very big for gyno. To big to believe that surgery is NOT the only course of action to take.
And for the rest of you who only read the bold print
When I post stuff I am speaking from personal knowledge. I've been using for over 12yrs and know many, many people who have gotten gyno. I've seen people use nolvadex out the ass and yes the gyno got small enough that it wasn't noticeable (which is probably what they really mean above) but the second they touch test again, boom, bitch titties all over again.
The only way to truly get rid of gyno is to have the tissue removed.
Last edited:
I just want to emphasize, if you are prone to gyno nolvadex will not cure it. It will not get rid of it. It will make it shrink but the very next time you touch dbol or test it will flair back up.
I've also spoken to my doc about gyno before and he said that there are only two resolutions to gyno in men, remove the source of estrogen or surgery. He said that there are no drugs that he knows of that will CURE gyno.
Also, another side note on nolvadex, over a year ago it was declared a possible carcinogen, which is why most doc's are pushing the further development of other drugs like arimidex and femara.
I've also spoken to my doc about gyno before and he said that there are only two resolutions to gyno in men, remove the source of estrogen or surgery. He said that there are no drugs that he knows of that will CURE gyno.
Also, another side note on nolvadex, over a year ago it was declared a possible carcinogen, which is why most doc's are pushing the further development of other drugs like arimidex and femara.
--------------------------------------------------------------------------------
FDA approves tamoxifen for reducing breast cancer risk
October 29, 1998
Web posted at: 3:09 p.m. EDT (1909 GMT)
WASHINGTON (CNN) -- The Food and Drug Administration on Wednesday approved the drug tamoxifen for reducing the risk of breast cancer in women at high risk for the disease.
Last March, a clinical trial by the National Cancer Institute was stopped early because researchers said there was sufficient evidence the tamoxifen reduced the chance of getting breast cancer by 44 percent.
However, the drug is not without side effects. The FDA said caution must be used in prescribing the drug because of its potentially serious side effects, including endometrial cancer and risk of blood clots which could lead to a stroke.
The FDA said the drug, manufactured by Zeneca Pharmaceuticals, Inc. of Wilmington, Delaware, is only for women at very high risk.
FDA approves tamoxifen for reducing breast cancer risk
October 29, 1998
Web posted at: 3:09 p.m. EDT (1909 GMT)
WASHINGTON (CNN) -- The Food and Drug Administration on Wednesday approved the drug tamoxifen for reducing the risk of breast cancer in women at high risk for the disease.
Last March, a clinical trial by the National Cancer Institute was stopped early because researchers said there was sufficient evidence the tamoxifen reduced the chance of getting breast cancer by 44 percent.
However, the drug is not without side effects. The FDA said caution must be used in prescribing the drug because of its potentially serious side effects, including endometrial cancer and risk of blood clots which could lead to a stroke.
The FDA said the drug, manufactured by Zeneca Pharmaceuticals, Inc. of Wilmington, Delaware, is only for women at very high risk.
As valuable as tamoxifen is to some patients, FDA strongly advises women and their doctors to carefully weight the benefits and risks of tamoxifen before patients use the drug," said FDA acting commissioner Michael Friedman, a cancer specialist.
Diana Zuckerman of the National Women's Health Network said she is very concerned that otherwise healthy women, who may never get cancer, could die from a stroke or endometrial cancer, a rare form of uterine cancer, because of the drug's side effects.
She said she is also concerned that the doctors who will be prescribing the medicine for protection will not be oncologists, but internists and general practitioners -- doctors who don't have a lot of experience with the drug.
The National Cancer Institute announced last week a massive breast cancer study that will compare tamoxifen with the osteoporosis drug raloxifen to see if raloxifen will prevent breast cancer with fewer side effects.
Diana Zuckerman of the National Women's Health Network said she is very concerned that otherwise healthy women, who may never get cancer, could die from a stroke or endometrial cancer, a rare form of uterine cancer, because of the drug's side effects.
She said she is also concerned that the doctors who will be prescribing the medicine for protection will not be oncologists, but internists and general practitioners -- doctors who don't have a lot of experience with the drug.
The National Cancer Institute announced last week a massive breast cancer study that will compare tamoxifen with the osteoporosis drug raloxifen to see if raloxifen will prevent breast cancer with fewer side effects.
But................ READ THE LAST LINE CAREFULLY (US study)
04/02/2001 - Updated 03:15 PM ET
Tamoxifen touted for men's heart disease
By Steve Sternberg, USA TODAY
The breast cancer drug tamoxifen may protect men from heart disease, just as estrogen lowers a woman's risk, new research indicates.
The drug appears to dilate blood vessels, boosting blood flow. It also cuts the amount of artery-clogging fats in the blood, reports Sarah Clarke of Papworth Hospital in Britain and colleagues at Cambridge University.
The findings "strongly support" larger trials of tamoxifen and its chemical cousin raloxifene for the treatment of men with coronary artery disease, the team recently reported in Circulation.
Tamoxifen and raloxifene are estrogen-like drugs that block receptors for natural estrogen — a hormone crucial to a woman's reproductive health.
Natural estrogen speeds tumor growth, but, paradoxically, also protects women from heart disease, a discovery that in the 1960s led doctors to try it in men.
That study ended disastrously.
Men who took estrogen suffered more heart attacks and deaths than those who didn't, perhaps because doctors prescribed five times the dose given to women. That was the last time doctors tested estrogen in men with heart disease.
In the '90s, studies in 3,000 women from Scotland and Sweden found tamoxifen reduced heart attack and death rates by 30% to 70%. A study of raloxifene's impact on heart disease is now underway in women.
Clarke and her team decided to carry out a small-scale study of tamoxifen in men to test their hypothesis that the drug also would lower heart-disease risk in men. The 56-day trial represents a rare reversal of the usual pattern in which drugs tested first in men are tried in women.
Doctors enrolled 31 men in the study. All took aspirin and cholesterol-lowering drugs. Sixteen were given tamoxifen. Tamoxifen also was given to a third group of 10 men with chest pain but no evidence of clogged arteries.
The researchers tested blood samples for a variety of blood fats that raise heart disease risk, including cholesterol and triglycerides.
Researchers also used ultrasound to measure the diameter of an artery in the arm. They found that estrogen dilated the volunteers' arteries and reduced their blood-fat levels.
Rita Redberg of the University of California-San Francisco cautioned that artery measurements of this type won't reveal whether the tamoxifen can actually prevent heart attacks or deaths.
Only studies following thousands of men for several years can do that, Redberg says.
"Tamoxifen is a drug we should look at in (large-scale) clinical trials," she says, adding, "I'd look at estrogen before I'd look at tamoxifen," because estrogen has twice the cholesterol-lowering potency of its synthetic cousins.
Giving estrogen to men at the standard dose given to women has a much broader margin of safety than the high-dose trial carried out in the '60s, Redberg says.
"No one has ever looked at estrogen in men at the doses we use in women," she notes.
04/02/2001 - Updated 03:15 PM ET
Tamoxifen touted for men's heart disease
By Steve Sternberg, USA TODAY
The breast cancer drug tamoxifen may protect men from heart disease, just as estrogen lowers a woman's risk, new research indicates.
The drug appears to dilate blood vessels, boosting blood flow. It also cuts the amount of artery-clogging fats in the blood, reports Sarah Clarke of Papworth Hospital in Britain and colleagues at Cambridge University.
The findings "strongly support" larger trials of tamoxifen and its chemical cousin raloxifene for the treatment of men with coronary artery disease, the team recently reported in Circulation.
Tamoxifen and raloxifene are estrogen-like drugs that block receptors for natural estrogen — a hormone crucial to a woman's reproductive health.
Natural estrogen speeds tumor growth, but, paradoxically, also protects women from heart disease, a discovery that in the 1960s led doctors to try it in men.
That study ended disastrously.
Men who took estrogen suffered more heart attacks and deaths than those who didn't, perhaps because doctors prescribed five times the dose given to women. That was the last time doctors tested estrogen in men with heart disease.
In the '90s, studies in 3,000 women from Scotland and Sweden found tamoxifen reduced heart attack and death rates by 30% to 70%. A study of raloxifene's impact on heart disease is now underway in women.
Clarke and her team decided to carry out a small-scale study of tamoxifen in men to test their hypothesis that the drug also would lower heart-disease risk in men. The 56-day trial represents a rare reversal of the usual pattern in which drugs tested first in men are tried in women.
Doctors enrolled 31 men in the study. All took aspirin and cholesterol-lowering drugs. Sixteen were given tamoxifen. Tamoxifen also was given to a third group of 10 men with chest pain but no evidence of clogged arteries.
The researchers tested blood samples for a variety of blood fats that raise heart disease risk, including cholesterol and triglycerides.
Researchers also used ultrasound to measure the diameter of an artery in the arm. They found that estrogen dilated the volunteers' arteries and reduced their blood-fat levels.
Rita Redberg of the University of California-San Francisco cautioned that artery measurements of this type won't reveal whether the tamoxifen can actually prevent heart attacks or deaths.
Only studies following thousands of men for several years can do that, Redberg says.
"Tamoxifen is a drug we should look at in (large-scale) clinical trials," she says, adding, "I'd look at estrogen before I'd look at tamoxifen," because estrogen has twice the cholesterol-lowering potency of its synthetic cousins.
Giving estrogen to men at the standard dose given to women has a much broader margin of safety than the high-dose trial carried out in the '60s, Redberg says.
"No one has ever looked at estrogen in men at the doses we use in women," she notes.
